BioVaxys Technology Corp.
BIOV
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 585.80K | 358.30K | 254.40K | 636.60K | 238.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 585.80K | 358.30K | 254.40K | 613.60K | 262.70K |
| Operating Income | -585.80K | -358.30K | -254.40K | -613.60K | -262.70K |
| Income Before Tax | -866.50K | -399.70K | 383.70K | -2.70M | -2.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -866.50K | -399.70K | 383.70K | -2.70M | -2.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -866.50K | -399.70K | 383.70K | -2.70M | -2.12M |
| EBIT | -585.80K | -358.30K | -254.40K | -613.60K | -262.70K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.02 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.02 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 220.08M | 208.25M | 145.27M | 145.23M | 146.82M |
| Average Diluted Shares Outstanding | 220.08M | 208.25M | 145.27M | 145.23M | 146.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
